Currently published data have demonstrated that anti-VEGF treatment by bevacizumab reduces blood supply, increases glycolytic metabolites, and promotes tumor metastasis in glioblastoma [51], underlining that no amelioration would be reached if inflammation-originated hypoxia has not been alleviated or abrogated. This evidence concerns the gene VEGFA and glioblastoma.